{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:20:05Z","timestamp":1788448805385,"version":"build-2803163510"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp and Dome","award":["IIS # 52754"],"award-info":[{"award-number":["IIS # 52754"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0238575","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T18:17:17Z","timestamp":1600366637000},"page":"e0238575","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV"],"prefix":"10.1371","volume":"15","author":[{"given":"Eug\u00e8nia","family":"Negredo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"Loste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"P\u00e9rez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Urrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Echeverr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bonjoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"pone.0238575.ref001","doi-asserted-by":"crossref","first-page":"e007428","DOI":"10.1136\/bmjopen-2014-007428","article-title":"A population-based study comparing patterns of care delivery on the quality of care for persons living with HIV in Ontario","volume":"5","author":"CE Kendall","year":"2015","journal-title":"BMJ Open"},{"key":"pone.0238575.ref002","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cid\/ciu701","article-title":"Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study","volume":"59","author":"J Schouten","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"pone.0238575.ref003","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/QAI.0b013e31825a3668","article-title":"HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group","volume":"60","author":"KP High","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0238575.ref004","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COH.0000000000000072","article-title":"HIV and aging: emerging research issues","volume":"9","author":"PW Hunt","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"pone.0238575.ref005","doi-asserted-by":"crossref","first-page":"5897298","DOI":"10.1155\/2017\/5897298","article-title":"Aging in HIV-Infected Subjects: A New Scenario and a New View","volume":"2017","author":"E Negredo","year":"2017","journal-title":"Biomed Res Int"},{"key":"pone.0238575.ref006","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/590150","article-title":"Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions","volume":"47","author":"RB Effros","year":"2008","journal-title":"Clin Infect Dis"},{"key":"pone.0238575.ref007","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.arr.2011.03.003","article-title":"Aging with multimorbidity: a systematic review of the literature","volume":"10","author":"A Marengoni","year":"2011","journal-title":"Ageing Res Rev"},{"key":"pone.0238575.ref008","doi-asserted-by":"crossref","first-page":"e114142","DOI":"10.1371\/journal.pone.0114142","article-title":"Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals","volume":"9","author":"M Massanella","year":"2014","journal-title":"PLoS One"},{"key":"pone.0238575.ref009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","article-title":"Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR","volume":"16","author":"Z Liu","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"pone.0238575.ref010","doi-asserted-by":"crossref","first-page":"e44454","DOI":"10.1371\/journal.pone.0044454","article-title":"Inflammation, coagulation and cardiovascular disease in HIV-infected individuals","volume":"7","author":"DA Duprez","year":"2012","journal-title":"PLoS One"},{"key":"pone.0238575.ref011","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1086\/605890","article-title":"Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells","volume":"200","author":"MA French","year":"2009","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref012","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/infdis\/jir134","article-title":"Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death","volume":"203","author":"DR Boulware","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref013","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1086\/652749","article-title":"Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection","volume":"201","author":"J Neuhaus","year":"2010","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref014","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"JL Lennox","year":"2009","journal-title":"Lancet (London, England)"},{"key":"pone.0238575.ref015","first-page":"1525","article-title":"Comorbidities Among US Patients With Prevalent HIV Infection-A Trend Analysis","volume":"216","author":"J Gallant","year":"2017","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref016","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3389\/fimmu.2017.01925","article-title":"Dynamics of CD4 and CD8 T-Cell Subsets and Inflammatory Biomarkers during Early and Chronic HIV Infection in Mozambican Adults","volume":"8","author":"L Pastor","year":"2017","journal-title":"Front Immunol"},{"key":"pone.0238575.ref017","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jamda.2013.05.009","article-title":"Proinflammatory cytokines, aging, and age-related diseases","volume":"14","author":"M Michaud","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"pone.0238575.ref018","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0000000000000066","article-title":"Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection","volume":"28","author":"MC Puertas","year":"2014","journal-title":"AIDS"},{"key":"pone.0238575.ref019","article-title":"Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from ART-suppressed HIV-infected individuals","author":"S Moron-Lopez","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pone.0238575.ref020","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/infdis\/jir060","article-title":"Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy","volume":"203","author":"PW Hunt","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref021","article-title":"Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological non-responders","author":"S Piconi","year":"2011","journal-title":"Blood"},{"key":"pone.0238575.ref022","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/infdis\/jiq115","article-title":"High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial","volume":"203","author":"A Ganesan","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials","volume":"50","author":"RT Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"pone.0238575.ref024","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","volume":"31","author":"M Toribio","year":"2017","journal-title":"AIDS"},{"key":"pone.0238575.ref025","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/infdis\/jiv194","article-title":"Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate\/Emtricitabine Plus Atazanavir\/Ritonavir, Darunavir\/Ritonavir, or Raltegravir","volume":"212","author":"TT Brown","year":"2015","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref026","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e328359f29c","article-title":"Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir","volume":"26","author":"E Mart\u00ednez","year":"2012","journal-title":"AIDS"},{"key":"pone.0238575.ref027","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/QAD.0b013e328359f20f","article-title":"Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery","volume":"26","author":"M Massanella","year":"2012","journal-title":"AIDS"},{"key":"pone.0238575.ref028","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects","volume":"16","author":"MJ Buz\u00f3n","year":"2010","journal-title":"Nat Med"},{"key":"pone.0238575.ref029","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1093\/jac\/dkt183","article-title":"Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy","volume":"68","author":"E Negredo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"pone.0238575.ref030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/infdis\/jiu015","article-title":"Will statins be an effective anti-inflammatory intervention for prevention of cardiovascular disease in patients with HIV?","volume":"209","author":"MP Dub\u00e9","year":"2014","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref031","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1310\/hct1303-153","article-title":"Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-\u03b1 in HIV-infected patients treated with ritonavir-boosted protease inhibitors","volume":"13","author":"L Calza","journal-title":"HIV Clin Trials"},{"key":"pone.0238575.ref032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct1501-1","article-title":"Tenofovir\/emtricitabine\/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients","volume":"15","author":"L Calza","journal-title":"HIV Clin Trials"},{"key":"pone.0238575.ref033","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/QAI.0000000000000478","article-title":"Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy","volume":"68","author":"NT Funderburg","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0238575.ref034","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/cid\/cit748","article-title":"Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy","volume":"58","author":"NT Funderburg","year":"2014","journal-title":"Clin Infect Dis"},{"key":"pone.0238575.ref035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3851\/IMP2752","article-title":"Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin","volume":"19","author":"M Auclair","year":"2014","journal-title":"Antivir Ther"},{"key":"pone.0238575.ref036","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/QAD.0000000000000526","article-title":"Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults","volume":"29","author":"KM Erlandson","year":"2015","journal-title":"AIDS"},{"key":"pone.0238575.ref037","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/cid\/cit053","article-title":"Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death","volume":"56","author":"ET Overton","year":"2013","journal-title":"Clin Infect Dis"},{"key":"pone.0238575.ref038","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/QAD.0000000000000443","article-title":"Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy","volume":"28","author":"L Galli","year":"2014","journal-title":"AIDS"},{"key":"pone.0238575.ref039","doi-asserted-by":"crossref","first-page":"e52828","DOI":"10.1371\/journal.pone.0052828","article-title":"Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study","volume":"8","author":"LD Rasmussen","year":"2013","journal-title":"PLoS One"},{"key":"pone.0238575.ref040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2018.12.016","article-title":"Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)","volume":"212","author":"SK Grinspoon","year":"2019","journal-title":"Am Heart J"},{"key":"pone.0238575.ref041","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection","volume":"5","author":"LH Kuller","year":"2008","journal-title":"PLoS Med"},{"key":"pone.0238575.ref042","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2009-03-210179","article-title":"Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation","volume":"115","author":"NT Funderburg","year":"2010","journal-title":"Blood"},{"key":"pone.0238575.ref043","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"NG Sandler","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref044","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/infdis\/jiq138","article-title":"A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response","volume":"203","author":"H Hatano","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3851\/IMP1917","article-title":"Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study","volume":"17","author":"JM Llibre","year":"2012","journal-title":"Antivir Ther"},{"key":"pone.0238575.ref046","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/01.aids.0000210617.90954.0e","article-title":"The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy","volume":"20","author":"E Negredo","year":"2006","journal-title":"AIDS"},{"key":"pone.0238575.ref047","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/infdis\/jiq071","article-title":"T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women","volume":"203","author":"RC Kaplan","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0238575.ref048","doi-asserted-by":"crossref","first-page":"e89444","DOI":"10.1371\/journal.pone.0089444","article-title":"Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging","volume":"9","author":"SA Lee","year":"2014","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0238575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T18:17:32Z","timestamp":1600366652000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0238575"}},"subtitle":[],"editor":[{"given":"Alan","family":"Winston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0238575","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]}}}